Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

(2012) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

(2012) Craig Leonardi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation

(2011) Yihua Cai et al.   IMMUNITY

Latitude and psoriasis prevalence

(2011) Christine C. Jacobson et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis

(2010) Andrea Chiricozzi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

(2010) W. Hueber et al.   Science Translational Medicine

IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines

(2009) Consuelo Ortega et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Psoriasis

(2009) Frank O. Nestle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells

(2008) Michelle A. Lowes et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY